FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072829009> ?p ?o ?g. }

• W2072829009 endingPage "S453" @default.
• W2072829009 startingPage "S453" @default.
• W2072829009 abstract "Purpose/Objective(s)To identify prognostic factors for overall survival (OS) and progression-free survival (PFS) for patients with uterine papillary serous carcinoma (UPSC).Materials/MethodsIRB approval was obtained for the study. Between January 2000 and 2010, 429 patients with endometrial cancer were diagnosed at our center and 62 were UPSC, International Federation of Gynecology and Obstetrics (FIGO) stages I–IV. All patients underwent hysterectomy. The pathological specimens were reviewed again independently by a single pathologist. The clinic-pathological features, adjuvant treatment, and relapse characteristics of 44 women with complete treatment information were analyzed to determine prognostic and predictive factors for OS and PFS using the Kaplan-Meier product limit method and log-rank tests.ResultsMedian follow-up was 49.3 months. Median OS was 50.4 months. Median PFS was not estimable. Two-year OS was 83% and decreased to 48% at 5 years. Two-year PFS was 82% and decreased to 75% at 5 years. Age (older), stage (higher), tumor size (larger), tumor not arising from a polyp, parametrial involvement, LVI and no adjuvant treatment, were prognostic factors associated with poorer OS (all p<0.05). Specifically, combined adjuvant chemotherapy and radiation therapy (Pelvic external beam ± Vaginal brachytherapy or vaginal brachytherapy alone) was significantly associated with longer OS as compared to no adjuvant treatment (p<0.0386). Higher stage and parametrial involvement were prognostic factors associated with poorer PFS (all p<0.05). OS and PFS had no significant association with race, depth of invasion, lower uterine segment involvement, peritoneal cytology, and lymph node involvement (p>0.05).ConclusionsIn uterine papillary serous cancer, adjuvant chemotherapy and radiation therapy as well as tumors arising from a polyp were associated with improved overall survival, while early stage disease was associated with improved progression free and overall survival. Purpose/Objective(s)To identify prognostic factors for overall survival (OS) and progression-free survival (PFS) for patients with uterine papillary serous carcinoma (UPSC). To identify prognostic factors for overall survival (OS) and progression-free survival (PFS) for patients with uterine papillary serous carcinoma (UPSC). Materials/MethodsIRB approval was obtained for the study. Between January 2000 and 2010, 429 patients with endometrial cancer were diagnosed at our center and 62 were UPSC, International Federation of Gynecology and Obstetrics (FIGO) stages I–IV. All patients underwent hysterectomy. The pathological specimens were reviewed again independently by a single pathologist. The clinic-pathological features, adjuvant treatment, and relapse characteristics of 44 women with complete treatment information were analyzed to determine prognostic and predictive factors for OS and PFS using the Kaplan-Meier product limit method and log-rank tests. IRB approval was obtained for the study. Between January 2000 and 2010, 429 patients with endometrial cancer were diagnosed at our center and 62 were UPSC, International Federation of Gynecology and Obstetrics (FIGO) stages I–IV. All patients underwent hysterectomy. The pathological specimens were reviewed again independently by a single pathologist. The clinic-pathological features, adjuvant treatment, and relapse characteristics of 44 women with complete treatment information were analyzed to determine prognostic and predictive factors for OS and PFS using the Kaplan-Meier product limit method and log-rank tests. ResultsMedian follow-up was 49.3 months. Median OS was 50.4 months. Median PFS was not estimable. Two-year OS was 83% and decreased to 48% at 5 years. Two-year PFS was 82% and decreased to 75% at 5 years. Age (older), stage (higher), tumor size (larger), tumor not arising from a polyp, parametrial involvement, LVI and no adjuvant treatment, were prognostic factors associated with poorer OS (all p<0.05). Specifically, combined adjuvant chemotherapy and radiation therapy (Pelvic external beam ± Vaginal brachytherapy or vaginal brachytherapy alone) was significantly associated with longer OS as compared to no adjuvant treatment (p<0.0386). Higher stage and parametrial involvement were prognostic factors associated with poorer PFS (all p<0.05). OS and PFS had no significant association with race, depth of invasion, lower uterine segment involvement, peritoneal cytology, and lymph node involvement (p>0.05). Median follow-up was 49.3 months. Median OS was 50.4 months. Median PFS was not estimable. Two-year OS was 83% and decreased to 48% at 5 years. Two-year PFS was 82% and decreased to 75% at 5 years. Age (older), stage (higher), tumor size (larger), tumor not arising from a polyp, parametrial involvement, LVI and no adjuvant treatment, were prognostic factors associated with poorer OS (all p<0.05). Specifically, combined adjuvant chemotherapy and radiation therapy (Pelvic external beam ± Vaginal brachytherapy or vaginal brachytherapy alone) was significantly associated with longer OS as compared to no adjuvant treatment (p<0.0386). Higher stage and parametrial involvement were prognostic factors associated with poorer PFS (all p<0.05). OS and PFS had no significant association with race, depth of invasion, lower uterine segment involvement, peritoneal cytology, and lymph node involvement (p>0.05). ConclusionsIn uterine papillary serous cancer, adjuvant chemotherapy and radiation therapy as well as tumors arising from a polyp were associated with improved overall survival, while early stage disease was associated with improved progression free and overall survival. In uterine papillary serous cancer, adjuvant chemotherapy and radiation therapy as well as tumors arising from a polyp were associated with improved overall survival, while early stage disease was associated with improved progression free and overall survival." @default.
• W2072829009 created "2016-06-24" @default.
• W2072829009 creator A5004977267 @default.
• W2072829009 creator A5010772620 @default.
• W2072829009 creator A5037328591 @default.
• W2072829009 creator A5048072937 @default.
• W2072829009 creator A5050728969 @default.
• W2072829009 creator A5051545264 @default.
• W2072829009 creator A5060132879 @default.
• W2072829009 date "2012-11-01" @default.
• W2072829009 modified "2023-09-26" @default.
• W2072829009 title "Outcome Determinants in Uterine Papillary Serous Carcinoma Based on Clinicopathological and Treatment Factors" @default.
• W2072829009 doi "https://doi.org/10.1016/j.ijrobp.2012.07.1200" @default.
• W2072829009 hasPublicationYear "2012" @default.
• W2072829009 type Work @default.
• W2072829009 sameAs 2072829009 @default.
• W2072829009 citedByCount "0" @default.
• W2072829009 crossrefType "journal-article" @default.
• W2072829009 hasAuthorship W2072829009A5004977267 @default.
• W2072829009 hasAuthorship W2072829009A5010772620 @default.
• W2072829009 hasAuthorship W2072829009A5037328591 @default.
• W2072829009 hasAuthorship W2072829009A5048072937 @default.
• W2072829009 hasAuthorship W2072829009A5050728969 @default.
• W2072829009 hasAuthorship W2072829009A5051545264 @default.
• W2072829009 hasAuthorship W2072829009A5060132879 @default.
• W2072829009 hasBestOaLocation W20728290091 @default.
• W2072829009 hasConcept C121608353 @default.
• W2072829009 hasConcept C126322002 @default.
• W2072829009 hasConcept C126838900 @default.
• W2072829009 hasConcept C143998085 @default.
• W2072829009 hasConcept C146357865 @default.
• W2072829009 hasConcept C151730666 @default.
• W2072829009 hasConcept C2776694085 @default.
• W2072829009 hasConcept C2777088508 @default.
• W2072829009 hasConcept C2777416452 @default.
• W2072829009 hasConcept C2779494336 @default.
• W2072829009 hasConcept C2780739268 @default.
• W2072829009 hasConcept C2780849966 @default.
• W2072829009 hasConcept C29456083 @default.
• W2072829009 hasConcept C50382708 @default.
• W2072829009 hasConcept C509974204 @default.
• W2072829009 hasConcept C71924100 @default.
• W2072829009 hasConcept C86803240 @default.
• W2072829009 hasConceptScore W2072829009C121608353 @default.
• W2072829009 hasConceptScore W2072829009C126322002 @default.
• W2072829009 hasConceptScore W2072829009C126838900 @default.
• W2072829009 hasConceptScore W2072829009C143998085 @default.
• W2072829009 hasConceptScore W2072829009C146357865 @default.
• W2072829009 hasConceptScore W2072829009C151730666 @default.
• W2072829009 hasConceptScore W2072829009C2776694085 @default.
• W2072829009 hasConceptScore W2072829009C2777088508 @default.
• W2072829009 hasConceptScore W2072829009C2777416452 @default.
• W2072829009 hasConceptScore W2072829009C2779494336 @default.
• W2072829009 hasConceptScore W2072829009C2780739268 @default.
• W2072829009 hasConceptScore W2072829009C2780849966 @default.
• W2072829009 hasConceptScore W2072829009C29456083 @default.
• W2072829009 hasConceptScore W2072829009C50382708 @default.
• W2072829009 hasConceptScore W2072829009C509974204 @default.
• W2072829009 hasConceptScore W2072829009C71924100 @default.
• W2072829009 hasConceptScore W2072829009C86803240 @default.
• W2072829009 hasIssue "3" @default.
• W2072829009 hasLocation W20728290091 @default.
• W2072829009 hasOpenAccess W2072829009 @default.
• W2072829009 hasPrimaryLocation W20728290091 @default.
• W2072829009 hasRelatedWork W2000647176 @default.
• W2072829009 hasRelatedWork W2014411809 @default.
• W2072829009 hasRelatedWork W2053104579 @default.
• W2072829009 hasRelatedWork W2053331699 @default.
• W2072829009 hasRelatedWork W2355670240 @default.
• W2072829009 hasRelatedWork W2362144381 @default.
• W2072829009 hasRelatedWork W2376593068 @default.
• W2072829009 hasRelatedWork W2734526255 @default.
• W2072829009 hasRelatedWork W4205904040 @default.
• W2072829009 hasRelatedWork W4246030040 @default.
• W2072829009 hasVolume "84" @default.
• W2072829009 isParatext "false" @default.
• W2072829009 isRetracted "false" @default.
• W2072829009 magId "2072829009" @default.
• W2072829009 workType "article" @default.